Akademik Veri Yönetim Sistemi
Indian Journal of Hematology and Blood Transfusion, 2026 (SCI-Expanded, Scopus)
Intravenous (IV) ferric carboxymaltose (FCM) is commonly used to treat iron deficiency (ID) but is frequently associated with hypophosphatemia. Predictors of clinically significant hypophosphatemia remain incompletely defined. In this retrospective cohort study, 202 adult patients who received intravenous FCM were evaluated. All patients underwent standardized laboratory assessment 7 days after their last IV FCM infusion. Clinically significant hypophosphatemia was defined as serum phosphorus < 2 mg/dL. Clinical variables, iron parameters, and markers of phosphate metabolism were analyzed. Logistic regression was used to identify factors associated with hypophosphatemia. Clinically significant hypophosphatemia occurred in 89 patients (44%), with most cases being mild to moderate. Baseline serum phosphorus was lower in the hypophosphatemic group (3.3 vs. 3.5 mg/dL, p = 0.001). The frequency of hypophosphatemia increased with FCM doses over 1000 mg. In multivariable analysis, newly diagnosed ID (OR 0.30, 95% CI 0.10–0.87), baseline serum phosphorus over 3.5 mg/dL (OR 0.34, 95% CI 0.18–0.63), and FCM dose < 1000 mg (OR 0.27, 95% CI 0.13–0.63) were independently associated with lower risk. Model discrimination was moderate (Area under the curve 0.71). Clinically significant hypophosphatemia following FCM is common but usually mild and transient. A prior history of ID, lower baseline phosphorus, and higher FCM doses are associated with increased risk. These observations may inform post-infusion monitoring strategies.